Histiocytosis

15 registered clinical trials studyying Histiocytosis — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Histiocytosis in Injecting Drug Users NCT06573671	Tampere University Hospital	—
Unknown	Characterizing Histiocytosis With 68Ga-FAPI PET/CT NCT05803629	Peking Union Medical College Hospital	N/A
Recruiting	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Recruiting	Histiocytic Disorder Follow-up Study NCT05915208	University of Alabama at Birmingham	—
Unknown	Molecular Targets for the Treatment of Histiocytosis NCT04437381	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocy NCT04943198	Anna Raciborska	Phase 2
Recruiting	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients NCT04943224	Anna Raciborska	Phase 2
Recruiting	Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging NCT04943211	Anna Raciborska	Phase 3
Active Not Recruiting	A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis NCT03127709	Memorial Sloan Kettering Cancer Center	—
Terminated	Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advance NCT02012231	Fore Biotherapeutics	Phase 1
Completed	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant NCT01049854	New York Medical College	Phase 2
Completed	Ceftriaxone in Non-neutropenic Fever NCT01225718	Vanderbilt University Medical Center	—
Completed	HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With NCT00145626	St. Jude Children's Research Hospital	Phase 2
Recruiting	Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study NCT04665674	Assistance Publique - Hôpitaux de Paris	—
Terminated	Unrelated Donor Transplant for Malignant and Non-Malignant Disorders NCT01050439	Columbia University	Phase 2